Literature DB >> 1811927

Effect of drug combinations on bilirubin-albumin binding.

A Robertson1, R Brodersen.   

Abstract

Drugs which compete with bilirubin for albumin binding may increase the risk of kernicterus. Fortunately, few drugs are strong competitors. However, in neonatology, many drugs are used simultaneously. We have studied the effect of drug combinations on bilirubin binding using human serum albumin and the peroxidase method. Combinations of aminophylline with phenobarbital, cefotaxime and vancomycin were studied as well as the combination of vancomycin and cefotaxime. The results show that the bilirubin-displacing effect of the drug combinations cannot be predicted from each drug's individual effect. These results are consistent with a flexible model of albumin binding. Combinations of drugs which are both albumin-bound and reach high serum concentrations should be tested for their combined effect on bilirubin binding and this information used in deciding on treatment in sick, premature infants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1811927     DOI: 10.1159/000457504

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  3 in total

1.  Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease.

Authors:  Kevin A Strauss; Donna L Robinson; Hendrik J Vreman; Erik G Puffenberger; Graham Hart; D Holmes Morton
Journal:  Eur J Pediatr       Date:  2006-01-25       Impact factor: 3.183

2.  Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants.

Authors:  W Oh; D K Stevenson; J E Tyson; B H Morris; C E Ahlfors; G Jesse Bender; R J Wong; R Perritt; B R Vohr; K P Van Meurs; H J Vreman; A Das; D L Phelps; T Michael O'Shea; R D Higgins
Journal:  Acta Paediatr       Date:  2010-01-25       Impact factor: 2.299

3.  Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?

Authors:  Helgi Padari; Kersti Oselin; Tõnis Tasa; Tuuli Metsvaht; Krista Lõivukene; Irja Lutsar
Journal:  BMC Pediatr       Date:  2016-12-08       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.